Because of the relatively short [[elimination half-life]] of elagolix, the actions of [[gonadotropin-releasing hormone]] (GnRH) are not fully blocked throughout the day.<ref name="EzzatiCarr2015" /><ref name="pmid19033369">{{cite journal | vauthors = Struthers RS, Nicholls AJ, Grundy J, Chen T, Jimenez R, Yen SS, Bozigian HP | title = Suppression of gonadotropins and estradiol in premenopausal women by oral administration of the nonpeptide gonadotropin-releasing hormone antagonist elagolix | journal = J. Clin. Endocrinol. Metab. | volume = 94 | issue = 2 | pages = 545–51 | year = 2009 | pmid = 19033369 | pmc = 2646513 | doi = 10.1210/jc.2008-1695 | url = }}</ref> For this reason, [[gonadotropin]] and [[sex hormone]] levels are only partially suppressed, and the degree of suppression can be dose-dependently adjusted as desired.<ref name="EzzatiCarr2015" /><ref name="pmid19033369" /> Moreover, if elagolix is discontinued, its effects are rapidly reversible.<ref name="EzzatiCarr2015" /><ref name="pmid19033369" /> Due to the suppression of [[estrogen]] levels by elagolix being incomplete, effects on [[bone mineral density]] are minimal, which is in contrast to first-generation [[GnRH analogue|GnRH inhibitor]]s.<ref name="pmid23885105">{{cite journal | vauthors = Diamond MP, Carr B, Dmowski WP, Koltun W, O'Brien C, Jiang P, Burke J, Jimenez R, Garner E, Chwalisz K | title = Elagolix treatment for endometriosis-associated pain: results from a phase 2, randomized, double-blind, placebo-controlled study | journal = Reprod Sci | volume = 21 | issue = 3 | pages = 363–71 | year = 2014 | pmid = 23885105 | doi = 10.1177/1933719113497292 | url = }}</ref><ref name="pmid25249568">{{cite journal | vauthors = Carr B, Dmowski WP, O'Brien C, Jiang P, Burke J, Jimenez R, Garner E, Chwalisz K | title = Elagolix, an oral GnRH antagonist, versus subcutaneous depot medroxyprogesterone acetate for the treatment of endometriosis: effects on bone mineral density | journal = Reprod Sci | volume = 21 | issue = 11 | pages = 1341–51 | year = 2014 | pmid = 25249568 | doi = 10.1177/1933719114549848 | pmc=4212335}}</ref> Moreover, the incidence and severity of [[menopausal]] [[side effect]]s such as [[hot flash]]es are also reduced relative to first-generation GnRH inhibitors.<ref name="EzzatiCarr2015" /><ref name="pmid19033369" />
